SEC 8-K
SEC 8-K: Item 5.02, 9.01
Official SEC filing update. Items: 5.02, 9.01.
Item 5.02, 9.01Accession 0000879407-26-000050
Arrowhead Pharmaceuticals (ARWR) Financials, Dividends & Stock Info
Explore comprehensive financial data for Arrowhead Pharmaceuticals, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (206 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
ARWRHealth Care
Arrowhead Pharmaceuticals (ARWR) is a biotechnology company. The company reports annual revenue of $829M and net loss of $2M. Its profit margin is -0.2%.
Arrowhead Pharmaceuticals Key Financials
Revenue (TTM)↑ 23258.2%
$829.4M
Net Income (TTM)↑ 99.7%
$-1.6M
Profit Margin
-0.2%
Top 81% in sector
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Arrowhead Pharmaceuticals Financial Health ScoreFY2025
0/100
Moderate health; several metrics need attention
+32 pts YoYProfitability23Liquidity70Growth100Cash Flow90Efficiency30
This Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Arrowhead Pharmaceuticals Official SEC Updates
Official filing updates from SEC EDGAR. Billiver stores internal evidence snapshots for verification, but this page links to the SEC source instead of republishing full filing text.
Open SEC filing
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0000879407-26-000047
SEC 8-K
SEC 8-K: Item 2.02, 9.01
Official SEC filing update. Items: 2.02, 9.01.
Item 2.02, 9.01Accession 0000879407-26-000045
SEC 8-K
SEC 8-K: Item 5.07, 9.01
Official SEC filing update. Items: 5.07, 9.01.
Item 5.07, 9.01Accession 0000879407-26-000037
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0000879407-26-000034
Source: SEC EDGAR · 5 filings
Informational only. Not investment advice.
Arrowhead Pharmaceuticals Recent Events
Leadership Change
Earnings Results
Shareholder Vote
Earnings Results
Material Agreement
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin MarginsProfit Margin-0.2%
vs 18.1% sector median / 15.0% avg
▼
Currently operating at a loss of 0 cents per dollar of revenue.
Revenue (TTM)$829M
Net Income (TTM)-$2M (Loss)
Profit margin 101% below sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Arrowhead Pharmaceuticals 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $829.4M(+23258.2%) | $3.6M(-97.4%) | $138.3M(+57.2%) | $88.0M(-36.4%) | $138.3M(+57.2%) | $88.0M(+180.2%) | $31.4M(+19736.5%) | $158,333(-58.6%) | $382,000(+141.3%) | $158,333(-45.5%) |
| Net Income | $-1,631,000(+99.7%) | $-599,493,000(-325.6%) | $-140,848,000(-66.6%) | $-84,553,000(+40.0%) | $-140,848,000(-66.6%) | $-84,553,000(-145.9%) | $-34,380,295(+57.9%) | $-81,723,002(+11.1%) | $-91,940,882(-341.7%) | $-20,815,860(+33.2%) |
| Total Assets | $1.4B | $1.1B | $765.6M | $691.9M | $710.1M | $522.5M | $349.8M | $111.6M | $104.0M | $128.2M |
| Total Debt | - | - | - | - | - | - | - | - | - | - |
| Total Equity | $466.1M | $185.4M | $271.3M | $398.5M | $408.8M | $461.8M | $244.6M | $95.8M | $81.4M | $95.6M |
| Profit Margin | -0.2% | -16882.4% | -101.8% | -96.1% | -101.8% | -96.1% | -109.5% | -51614.6% | -24068.3% | -13146.9% |
| ROE | -0.4% | -323.3% | -51.9% | -21.2% | -34.4% | -18.3% | -14.1% | -85.3% | -112.9% | -21.8% |
| ROA | -0.1% | -52.6% | -18.4% | -12.2% | -19.8% | -16.2% | -9.8% | -73.2% | -88.4% | -16.2% |
Quarterly Financials
Last 8 quarters| Metric | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $545.2M | $2.5M | $3.6M | $3.6M | $3.6M | $224.6M | $208.8M | $62.5M |
| Net Income | $197.4M | $-173,085,000 | $-428,957,000 | $-258,164,000 | $-132,864,000 | $-95,596,000 | $7.3M | $-41,325,000 |
| Total Assets | $1.4B | $1.4B | $1.1B | $1.1B | $1.1B | $765.6M | $765.6M | $765.6M |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Insider Trading
Loading chart...
Loading transactions...
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Arrowhead Pharmaceuticals Free Cash Flow & Dividend Coverage
Free Cash Flow
$156.9M
FY2025
FCF Margin
18.9%
FCF / Revenue
Operating Cash Flow
$179.6M
Cash from operations
FCF / Net Income
-96.19x
Below earnings
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$64.4M | -$65.7M | -$64.4M | -$23.9M | -$95.8M | $171.3M | -$95.8M | $171.3M | -$462.9M | $179.6M |
| CapEx | -$3.9M | -$2.0M | -$3.9M | -$7.9M | -$12.0M | -$23.6M | -$12.0M | -$23.6M | -$141.5M | -$22.7M |
| Free Cash Flow | -$68.3M | -$67.7M | -$68.3M | -$31.9M | -$107.8M | $147.7M | -$107.8M | $147.7M | -$604.3M | $156.9M |
| FCF Margin | -43129.2% | -17716.8% | -43129.2% | -101.4% | -122.5% | 106.8% | -122.5% | 106.8% | -17018.3% | 18.9% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Arrowhead Pharmaceuticals Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for ARWR.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Arrowhead Pharmaceuticals FAQ
What is Arrowhead Pharmaceuticals's annual revenue?
Arrowhead Pharmaceuticals (ARWR) reported $829 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Arrowhead Pharmaceuticals profitable?
Arrowhead Pharmaceuticals reported a net loss with a -0.2% profit margin, totaling $2 million in net losses (TTM). All figures from SEC EDGAR 10-K filings.
Does Arrowhead Pharmaceuticals pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) does not currently pay dividends to shareholders.
What is Arrowhead Pharmaceuticals's financial health score?
Arrowhead Pharmaceuticals has a financial health score of 60/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Arrowhead Pharmaceuticals financial data are available?
10 years of financial data are available for Arrowhead Pharmaceuticals from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.